For HIV patients with a suppressed viral load, the standard formula has long been three drugs in one tablet, taken daily. On April 21, 2026, the FDA approved a drug that requires only two. Idvynso, developed by Merck, demonstrated comparable efficacy to the current market leader BIKTARVY in head-to-head trials and outperformed several standard therapies in a second study.
Why Fewer Active Ingredients Can Be Better
Around 1.2 million people in the United States live with HIV, the majority with a viral load below the limit of detection. This viral suppression is achieved today with once-daily combination pills that typically contain three active ingredients. These triple therapies are reliable but carry drawbacks that accumulate over decades.
Tenofovir, a common component, can strain the kidneys and bones over the long term. Integrase inhibitors (INSTIs), the other backbone of standard therapies, have been linked to weight gain and no longer work for patients who have developed resistance. For patients with certain comorbidities or who cannot tolerate tenofovir, alternatives have remained limited.
How Idvynso Works
Idvynso combines two active ingredients from different drug classes. Doravirine is an established non-nucleoside reverse transcriptase inhibitor (NNRTI). Islatravir belongs to a newer class, the nucleoside reverse transcriptase translocation inhibitors (NRTTIs). The compound not only blocks the reverse transcriptase enzyme but also disrupts its translocation, a movement step required for viral replication, making it mechanistically distinct from classic NRTIs and INSTIs.
The drug contains neither tenofovir nor an integrase inhibitor. It is the first two-drug therapy that avoids both drug classes while remaining available as a once-daily oral tablet. Idvynso is approved exclusively as a switch therapy for patients who are already virally suppressed, have no history of treatment failure, and have no known resistance to doravirine.
Trial Results
Two Phase 3 studies with more than 1,000 participants in total formed the basis for approval.
In Study 052, 342 of 513 virally suppressed patients switched from BIKTARVY, currently the most commonly prescribed HIV combination drug, to Idvynso. The remaining 171 stayed on BIKTARVY. After 48 weeks, the viral suppression rate was 92 percent in the Idvynso group and 94 percent in the BIKTARVY group. Statistical non-inferiority was confirmed.
In Study 051, Idvynso was numerically superior: 96 percent of the 366 patients on Idvynso remained virally suppressed, compared with 92 percent of the 185 patients on various standard therapies. Only 1 percent of the Idvynso group exceeded a viral load of 50 copies per milliliter, compared with 5 percent in the comparator group.
The most commonly reported side effects in both studies were diarrhea, dizziness, fatigue, and headache. The frequency was broadly comparable to the comparator therapies.
Who the Drug Is For
Idvynso is not a drug for newly diagnosed HIV patients. It is intended exclusively for virally suppressed adults who are already on a stable antiretroviral regimen and have no resistance to doravirine. It is not approved for patients with a history of treatment failure.
This positions Idvynso as an option for a large and growing segment of the HIV population: long-term patients who are stable on therapy and seeking better-tolerated alternatives. Patients with kidney problems or low bone density who do not tolerate tenofovir well stand to benefit most.
Outlook
Idvynso will be available in US pharmacies from May 11, 2026. Merck has not yet announced a price. Since the drug competes directly with BIKTARVY, marketed by Gilead Sciences, a competitive price point is expected.
For the HIV treatment market, the approval signals a shift: for the first time, virally suppressed patients have a fully oral option without an INSTI or tenofovir. Several other two-drug therapies, including monthly depot injections, are in development. Idvynso is the first to occupy this therapeutic space with an oral tablet.